Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Jul 14;11(26):4003-7.
doi: 10.3748/wjg.v11.i26.4003.

Radiosensitivity of human colon cancer cell enhanced by immunoliposomal docetaxel

Qing-Wei Wang  1 , Hui-Lan Lu, Chang-Cheng Song, Hong Liu, Cong-Gao Xu
Affiliations

Radiosensitivity of human colon cancer cell enhanced by immunoliposomal docetaxel

Qing-Wei Wang et al. World J Gastroenterol. .

Abstract

Aim: To enhance the radiosensitivity of human colon cancer cells by docetaxel.

Methods: Immunoliposomal docetaxel was prepared by coupling monoclonal antibody against carcinoembryonic antigen to cyanuric chloride at the PEG terminus of liposome. LoVo adenocarcinoma cell line was treated with immunoliposomal docetaxel or/and irradiation. MTT colorimetric assay was used to estimate cytotoxicity of immunoliposomal docetaxel and radiotoxicity. Cell cycle redistribution and apoptosis were determined with flow cytometry. Survivin expression in LoVo cells was verified by immunohistochemistry. D801 morphologic analysis system was used to semi-quantify immunohistochemical staining of survivin.

Results: Cytotoxicity was induced by immunoliposomal docetaxel alone in a dose-dependent manner. Immunoli-posomal docetaxel yielded a cytotoxicity effect at a low dose of 2 nmol/L. With a single dose irradiation, the relative surviving fraction of LoVo cells showed a dose-dependent response, but there were no significant changes as radiation delivered from 4 to 8 Gy. Compared with liposomal docetaxel or single dose irradiation, strongly radiopotentiating effects of immunoliposomal docetaxel on LoVo cells were observed. A low dose of immunoliposomal docetaxel could yield sufficient radiosensitivity. Immunoliposomal docetaxel were achieved both specificity of the conjugated antibody and drug radiosensitization. Combined with radiation, immunoliposomal docetaxel significantly increased the percentage of G(2)/M cells and induced apoptosis, but significantly decreased the percentage of cells in G(2)/G(1) and S phase by comparison with liposomal docetaxel. Immunohistochemical analysis showed that the brown stained survivin was mainly in cytoplasm of LoVo cells. Semi-quantitative analysis of the survivin immunostaining showed that the expression of survivin in LoVo cells under irradiation with immunoliposomal docetaxel was significantly decreased.

Conclusion: Immunoliposomal docetaxel is strongly effective for target radiosensitation in LoVo colon carcinoma cells, and may offer the potential to improve local radiotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cytotoxicity of immunoliposomal docetaxel to LoVo cells.
Figure 2
Figure 2
Radiotoxicity to LoVo cells irradiated with single doses.
Figure 3
Figure 3
Target radiopotentiating effects of docetaxel immunoliposomes on LoVo cells.
Figure 4
Figure 4
Combined of effect immunoliposomal docetaxel and radiation on cell cycle distribution and apoptosis.
Figure 5
Figure 5
Expression of survivin in LoVo cells.
Figure 6
Figure 6
Survivin expression in LoVo cells were determined by quantitative image analysis.
See this image and copyright information in PMC

References

    1. Shunyakov L, Ryan CK, Sahasrabudhe DM, Khorana AA. The influence of host response on colorectal cancer prognosis. Clin Colorectal Cancer. 2004;4:38–45. - PubMed
    1. Sarid D, Wigler N, Gutkin Z, Merimsky O, Leider-Trejo L, Ron IG. Cutaneous and subcutaneous metastases of rectal cancer. Int J Clin Oncol. 2004;9:202–205. - PubMed
    1. Munro AJ, Bentley AH. Deprivation, comorbidity and survival in a cohort of patients with colorectal cancer. Eur J Cancer Care (Engl) 2004;13:254–262. - PubMed
    1. Hahnloser D, Haddock MG, Nelson H. Intraoperative radiotherapy in the multimodality approach to colorectal cancer. Surg Oncol Clin N Am. 2003;12:993–1013, ix. - PubMed
    1. Höcht S, Hammad R, Thiel HJ, Wiegel T, Siegmann A, Willner J, Wust P, Herrmann T, Eble M, Flentje M, et al. Recurrent rectal cancer within the pelvis. A multicenter analysis of 123 patients and recommendations for adjuvant radiotherapy. Strahlenther Onkol. 2004;180:15–20. - PubMed

Publication types